SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-009683
Filing Date
2024-03-12
Accepted
2024-03-12 17:00:48
Documents
60
Period of Report
2024-01-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 613657
2 ex31-1.htm EX-31.1 17855
3 ex31-2.htm EX-31.2 17904
4 ex32-1.htm EX-32.1 6998
5 ex32-2.htm EX-32.2 7062
  Complete submission text file 0001493152-24-009683.txt   3746067

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE anix-20240131.xsd EX-101.SCH 29177
7 XBRL CALCULATION FILE anix-20240131_cal.xml EX-101.CAL 39747
8 XBRL DEFINITION FILE anix-20240131_def.xml EX-101.DEF 140849
9 XBRL LABEL FILE anix-20240131_lab.xml EX-101.LAB 250596
10 XBRL PRESENTATION FILE anix-20240131_pre.xml EX-101.PRE 204348
62 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 524223
Mailing Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118
Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118 408-708-9808
Anixa Biosciences Inc (Filer) CIK: 0000715446 (see all company filings)

IRS No.: 112622630 | State of Incorp.: DE | Fiscal Year End: 1031
Type: 10-Q | Act: 34 | File No.: 001-37492 | Film No.: 24743116
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)